Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma

Model scores of the 29,894 trials active now.

Model score 14% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 22% of the time (1,598 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2026-02-10. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past trials: 2681 (raises risk) · Sponsor's track record
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: celltransplantcancerskinto determine
  Phrases that lowered it: participantmultiplepharmacokineticsparticipantsmyeloma
• Phase: 2 (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 92 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 35.4% (raises risk) · Drug's FDA history
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: parallel (raises risk) · Design
• Sponsor's past termination rate: 7.1% (lowers risk) · Sponsor's track record
• Number of arms: 5 (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Responsible party: sponsor (lowers risk) · Design
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Drug's FAERS reports marked serious: 85.7% (lowers risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM NCT06160609 · started 2019 · scored riskier than 35% of active trials terminated
• Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM NCT06655818 · started 2021 · scored riskier than 43% of active trials terminated
• A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma NCT05556616 · started 2023 · scored riskier than 26% of active trials terminated
• Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma NCT04896658 · started 2021 · scored riskier than 64% of active trials terminated
• A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody NCT03525678 · started 2018 · scored riskier than 52% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.